Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from biotechnology

HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty

Given the uncertainty, HC Wainwright moderated its COVID-19 franchise estimates, the primary driver of estimate reductions, and price target reduction to $125 (from $200) on Vir Biotechnology Inc (NASDAQ:VIR). The analyst maintained a Buy rating on VIR shares. The analyst continues to view Vir's platform, validated with successful antiviral therapies against Ebola and COVID-19, and pipeline,…

Benzinga

Cathie Wood Watch: Ark Buys Adaptive Biotech, Smart-Glasses Maker

Ark ETFs bought and sold biotechnology stocks. Ark's flagship fund trails the S&P 500 over the past five years.

The Street

Recap: PDS Biotechnology Q1 Earnings

PDS Biotechnology (NASDAQ:PDSB) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More

Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ: IBB), considered a proxy for the sector, shed close to 3 percent during the week.

Benzinga

Biotechnology brains flock to regional Australia, but trials still based in metro areas

Much of Australia's biotech sector is based in regional Australia, but a lack of adequate, but a lack of adequate infrastructure means country patients are still missing out on the early stages of groundbreaking trials.

ABC News

Where Vir Biotechnology Stands With Analysts

Within the last quarter, Vir Biotechnology (NASDAQ:VIR) has observed the following analyst ratings:

Benzinga

Earnings Outlook For Vir Biotechnology

Vir Biotechnology (NASDAQ:VIR) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Vir Biotechnology will report an earnings per share (EPS) of $3.78.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Why HC Wainwright Is Bullish On This Stock's Hepatitis-B Pipeline

Recently, Vir Biotechnology Inc (NASDAQ:VIR) announced updates on its expansive hepatitis portfolio, including VIR-2218 which is part of a collaboration with Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), and VIR-3434, a monoclonal antibody (mAb). The key highlight of the event was the initial data presented from the Phase 2 MARCH trial of VIR-2218 + VIR-3434 in patients with…

Benzinga

Former ski resorts owner faces sentencing in Vermont fraud

The former owner of two Vermont ski resorts is facing sentencing for his role in a failed plan to build a biotechnology plant in Vermont using tens of millions of dollars in foreign investors’ money raised through a special visa program that was part of the largest fraud case in…

The Independent UK

Rajesh Gokhale gets addl charge of Director-General CSIR

Secretary of Department of Biotechnology Rajesh S Gokhale on Friday was given additional charge of the post of Director-General, Council of Scientific and Industrial Research (CSIR)-cum-Secretary, Department of Scientific and Industrial Research. Full story on Dynamite News:

Dynamite News

The racism chronicle

The film that took Akshun Abhi, all of 24 years, and the team of 7 Rounds to Cannes is based on last year’s Kansas racial killing in which a 51-year-old Navy veteran shot an Indian techie who was enjoying a drink with a friend in a pub.“Suddenly, this man walked…

Newslaundry

1 … 6 7 8 9

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Securities and Exchange Commission

Alnylam Pharmaceuticals Inc

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.